A growing body of literature, including randomized clinical trials (RCTs), meta-analyses, and guideline statements, supports the complementary mechanisms and potential benefits of combined SGLT2i and GLP-1RA therapy, yet important questions remain regarding how best to implement this strategy in clinical practice [10, 15,16,17,18]
CMS was aiming for a critical mass of Part D sponsors to participate and established a threshold participation rate of 80% for 2027
GLP-1 drugs influence hunger by altering communication between the gut and the brain, and they can cause side effects that include appetite loss, decreased muscle mass, and gastrointestinal discomfort
After adjusting for age and baseline characteristics, semaglutide was associated with a 12% lower risk of incident diabetes compared with liraglutide (HR 0.88
Improvement of insulin resistance : GLP-1RA was shown to improve insulin signaling in the brain and promote glucose metabolism